GET /metagenomics/api/v1/samples/ERS2522721/studies?format=api
HTTP 200 OK
Allow: GET, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept
{
"links": {
"first": "https://www.ebi.ac.uk/metagenomics/api/v1/samples/ERS2522721/studies?format=api&page=1",
"last": "https://www.ebi.ac.uk/metagenomics/api/v1/samples/ERS2522721/studies?format=api&page=1",
"next": null,
"prev": null
},
"data": [
{
"type": "studies",
"id": "MGYS00002397",
"attributes": {
"accession": "MGYS00002397",
"samples-count": 83,
"bioproject": "PRJEB27076",
"is-private": false,
"last-update": "2018-06-08T13:36:21",
"secondary-accession": "ERP109116",
"centre-name": "NTNU",
"public-release-date": null,
"study-abstract": "Introduction: 5- aminosalicylic acid (5-ASA) is the mainstay of treatment of patients with ulcerative colitis (UC). 5-ASA acts locally in the colonic mucosa and mucosal concentrations of 5-ASA are inversely correlated to disease activity. Previous studies have found large inter-individual variations in mucosal 5-ASA concentrations. Several explanatory models have been proposed, but is remains unintelligible why some patients have high 5-ASA concentrations, while others have low. Previous findings suggest that treatment with Asacol (pH-dependent release formulation) yields higher mucosal 5-ASA concentrations than Pentasa (time-dependent release formulation). The mucosal bacterial composition and fermentation products, such as short chain fatty acids, greatly impact pH-value in the colon and might therefore be correlated to 5-ASA concentration. Aim and method: In this cross-sectional non-randomized study, we have measured mucosal concentration of 5-ASA and its inactive metabolite acetyl-5-ASA (Ac-5-ASA) in the left hemicolon and rectum in patients with quiescent UC taking Mezavant, Asacol or Pentasa. Patients with quiescent UC using oral mesalazine monotherapy in the maximal dose recommended by the manufacturers (4.0-4.8g o.d.) were included. Eight hours after ingestion of mesalazine, patients underwent blood sample collection, followed by bowel preparation with enema and sigmoidoscopy. A total of six mucosal biopsies were collected 10, 25 and 40 cm from the anal verge. 5-ASA and Ac-5-ASA concentrations were measured in five biopsies and serum by high-performance liquid chromatography. The mucosal and fecal microbiome was explored using 16srRNA sequencing. Disease activity was assessed by Mayo score (MS), Geboes histological score (GS) and measurement of plasma ESR, CRP, blood leukocytes and fecal calprotectin concentrations.",
"study-name": "Mucosal microbiome and 5-ASA concentration in the left hemicolon and rectum in patients with quiescent ulcerative colitis",
"data-origination": "SUBMITTED"
},
"relationships": {
"analyses": {
"links": {
"related": "https://www.ebi.ac.uk/metagenomics/api/v1/studies/MGYS00002397/analyses?format=api"
}
},
"publications": {
"links": {
"related": "https://www.ebi.ac.uk/metagenomics/api/v1/studies/MGYS00002397/publications?format=api"
}
},
"samples": {
"links": {
"related": "https://www.ebi.ac.uk/metagenomics/api/v1/studies/MGYS00002397/samples?format=api"
}
},
"biomes": {
"links": {
"related": "https://www.ebi.ac.uk/metagenomics/api/v1/studies/MGYS00002397/biomes?format=api"
},
"data": [
{
"type": "biomes",
"id": "root:Host-associated:Human:Digestive system:Large intestine:Sigmoid colon",
"links": {
"self": "https://www.ebi.ac.uk/metagenomics/api/v1/biomes/root:Host-associated:Human:Digestive%20system:Large%20intestine:Sigmoid%20colon?format=api"
}
}
]
},
"downloads": {
"links": {
"related": "https://www.ebi.ac.uk/metagenomics/api/v1/studies/MGYS00002397/downloads?format=api"
}
},
"geocoordinates": {
"links": {
"related": "https://www.ebi.ac.uk/metagenomics/api/v1/studies/MGYS00002397/geocoordinates?format=api"
}
}
},
"links": {
"self": "https://www.ebi.ac.uk/metagenomics/api/v1/studies/MGYS00002397?format=api"
}
}
],
"meta": {
"pagination": {
"page": 1,
"pages": 1,
"count": 1
}
}
}